Prognostic value of the Island sign for hematoma expansion and functional outcome after intracerebral hemorrhage: a systematic review and meta-analysis.

J Clin NeurosciJul 28, 2026 (epub)
Clinical ResearchNeurologyRadiology (Diagnostic)

Maria Clara Nery Cardoso, Davi Chaves Rocha de Souza, Maianna Sancho Lago et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of the Island Sign (IS) in 9,459 patients with spontaneous intracerebral hemorrhage (ICH). The study found that patients with IS had significantly higher odds of poor functional outcomes (OR 2.77) and hematoma expansion (OR 2.75), indicating its relevance for risk stratification and management.

Key findings

  • Patients with IS had poor functional outcomes with an odds ratio of 2.77.
  • Hematoma expansion was more likely in patients with IS, with an odds ratio of 2.75.
  • Overall mortality rate was higher in patients with IS, with an odds ratio of 2.54.

Why it matters

Understanding the implications of the Island Sign can aid clinicians in identifying patients at higher risk for complications following intracerebral hemorrhage, potentially guiding treatment decisions and improving patient outcomes.

Source

PubMed · PMID 42520487

Published in J Clin Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.